India Pharma 2026 Highlights Dual Strategy for Pharmaceutical Growth
At the India Pharma 2026 conference held on Tuesday, key leaders from the pharmaceutical industry outlined a comprehensive vision for the sector's future. They stressed that India must maintain its stronghold in generic medicines while simultaneously accelerating efforts in innovative drug development. This dual approach is seen as essential to address the country's diverse and significant disease burden effectively.
Targeting Niche Segments and Rare Diseases
Industry experts highlighted a strategic opportunity for domestic companies, particularly small to mid-sized players, to establish a robust presence in specialized areas. By focusing on rare diseases and niche patient segments, these firms can leverage their agility and specialized research capabilities to drive meaningful breakthroughs. Pankaj Patel, past president of Ficci and chairman of Zydus Lifesciences, emphasized that this targeted strategy is crucial given India's vast healthcare challenges.
Patel further elaborated on the importance of creating a sustainable market for innovative therapies. He noted that building parallel reimbursement mechanisms through insurance, government support, or alternative financing models will be critical to ensure that breakthrough treatments are not only developed but also accessible to patients across the country.
Boosting Research and Development Investment
In line with the long-term vision of developing 100 new drugs by 2047, Patel called for a substantial increase in research and development (R&D) investment. Currently, R&D spending in the Indian pharmaceutical industry hovers around 6–7% of turnover. To achieve ambitious innovation goals, this needs to rise significantly to 12–15%. Such a boost would fuel more advanced research and support the development of novel therapeutics.
Operationalizing the RDI Fund
A key development discussed at the conference was the Research Development Innovation (RDI) fund, a Rs 1 lakh crore scheme announced last year. Anchored by the Department of Science and Technology and operationalized through the Anusandhan National Research Foundation (ANRF), this initiative is expected to be rolled out this year following the recent appointment of two fund managers, including BIRAC.
Shivkumar Kalyanaraman, CEO of ANRF, detailed the evolving research funding architecture. He explained that the RDI fund combines grant-based support for academia and not-for-profit institutions with capital-based instruments tailored for the private sector. This hybrid model aims to foster collaboration and drive innovation across the entire ecosystem.
Economic Returns and Funding Challenges
Anirudh Roy Popli, a partner at McKinsey, reinforced the economic case for increased investment in pharmaceutical innovation. He pointed out that such investments can yield up to fourfold returns, making a strong argument for scaling funding efforts industry-wide. However, Sunil Thakur, Partner and IC Member at Quadria Capital and Co-founder of HealthQuad, highlighted persistent challenges.
Thakur noted that despite India's strong pharmaceutical fundamentals, the lack of deep risk capital and a robust exit ecosystem remains a critical constraint. These gaps hinder the scaling of innovation and limit the sector's ability to fully capitalize on its potential. Addressing these issues will be vital for sustaining long-term growth and competitiveness in the global market.
The insights from India Pharma 2026 underscore a pivotal moment for the Indian pharmaceutical industry. By embracing a balanced strategy of generics and innovation, targeting niche markets, and overcoming funding hurdles, the sector can enhance its global standing and better serve patient needs domestically and internationally.
